Robert Gadimian, owner of privately held company Rophe Pharma, announced they were assigned product code RPHE-7193 for the rights to
NEW HOPE IN FIGHT AGAINST HAIR LOSS
Robert Gadimian, owner of privately held company Rophe Pharma, announced they were assigned product code RPHE-7193 for the rights to an exciting new treatment to fight hair loss. The treatment comes in the form of a topical application using hydralazine to promote hair growth. The background for hydralazine in RPHE-7193 is almost the same as minoxidil, the active substance in Rogaine. Hydralazine, like minoxidil, is a blood pressure drug with hair growth as side effect.
SUPERIOR HAIR GROWTH
According to Gadimian, hydralazine is demonstrating to be a much superior hair growth compound compared to minoxidil. In the exploratory study that is going on with 12 men, substantial hair growth is being observed after 4-8 weeks of use in men up to age 65. It should be noted that Rogaine starts to show its effect after 4 months of treatment. The two already approved drugs for male pattern baldness (MPB), Rogaine and Propecia, have not been studied in men above age 41 but Robert Gadimian is testing RPHE-7193 in that age group — since as mentioned above, most of the men who suffer from hair loss are above age 41 — a fact the FDA told the Rogaine developers during its development.
GOODBYE TO SCALP IRRITATION
RPHE-7193 does not contain alcohol and polyethylene glycol, the two solvents in Rogaine that cause skin irritation and sensitivity, hence RPHE-7193 is expected to have a better skin related safety profile than Rogaine.
ROPHE PHARMA NEW PRODUCT FIGHTS HAIR LOSS
According to the America Hair Loss Association, MPB – also referred to as androgenetic alopecia — accounts for more than 95% of hair loss in men. By the age of 35, two-thirds of American men will experience some degree of appreciable hair loss; by the age of fifty, approximately 85% of men will contend with significantly thinning hair. Approximately 25% of men who suffer with MPB began the painful process of losing their hair before reaching the age of 21. For men unhappy with MPB the effects can be wide-ranging and affect quality of life, both personal and professional. In spite of this wide spread issue, no drug has been able to satisfactorily solve MPB in men. The available treatments include Rogaine, that has a nonsatisfactory hair growth effect, takes a long time to work and has skin irritation side effects or Propecia, which mainly preserves the hair that men have and does little to regrow hair as well as having some serious sexual side effects for men. By making the topical application of hydralazine widely available, Rophe Pharma and Gadimian are bringing a much-welcomed alternative treatment to market.